1. The haemodynamic response to acute central hypovolaemia consists of two
phases. During phase I, arterial pressure is well maintained in the face of
falling cardiac output (CO) by baroreceptor-mediated reflex vasoconstricti
on and cardio-acceleration. Phase II commences once CO has fallen to a crit
ical level of 50-60% of its resting value, equivalent to loss of approximat
ely 30% of blood volume.
2. During phase II, sympathetic vasoconstrictor and cardiac drive fall abru
ptly and cardiac vagal drive increases. In humans, this response is invaria
bly associated with fainting and has been termed vasovagal syncope.
3. In both experimental animals and in humans, the responses to acute centr
al hypovolaemia are greatly affected by anaesthetic agents, in that the com
pensatory responses during phase I (e.g. halothane) or their failure during
phase II (e.g. alfentanil) are blunted or abolished.
4. Therefore, our present knowledge of the neurochemical basis of the respo
nse to hypovolaemia depends chiefly on the results of experiments in consci
ous animals. Use of techniques for simulating haemorrhage has greatly enhan
ced this research effort, by allowing the effects of multiple treatments on
the response to acute central hypovolaemia to be tested in the same animal
.
5. The results of such experiments indicate that phase II of the response t
o hypovolaemia is triggered, at least in part, by a signal from cardiac vag
al afferents. There is also strong evidence that phase II depends on brains
tem delta (1)-opioid receptor and nitrergic mechanisms and can potentially
be modulated by circulating or neuronally released adrenocorticotropic horm
one, brainstem serotonergic pathways operating through 5-HT1A receptors and
opioids acting through mu- and kappa -opioid receptors in the brainstem.
6. Phase II also appears to require input from supramedullary brain centres
. Future studies should determine how these neurotransmitter systems intera
ct and their precise neuroanatomical arrangements.